Skip to main content
Fig. 1 | Cancer Nanotechnology

Fig. 1

From: Hyaluronated nanoparticles deliver raloxifene to CD44-expressed colon cancer cells and regulate lncRNAs/miRNAs epigenetic cascade

Fig. 1

Chemistry, TEM imaging, and cumulative drug release of nanoparticles. A] RX-CS NPs and RX-HA-CS NPs schematic diagram of their preparation, B, C, D] TEM images of the raloxifene synthesized nanoparticles. B] TEM image of formula 1 of the RX-CS NPs (F1), C] TEM image of formula 2 of the RX-CS NPs (F2), D] A magnified RX-HA-CS NPs shows the encapsulated drug (RX) inside the core and a rounded shell of CS linked with chains of HA that target cancer cells through the overexpressed CD44 receptors on their membranes. E] Cumulative drug release profiling of RX, RX-CS NPs (F1), RX-CS NPs (F2), and RX-HA-CS NPs. RX raloxifene, HA hyaluronic acid, CS chitosan, NPs nanoparticles

Back to article page

Cancer Nanotechnology

ISSN: 1868-6966

Contact us